2022 World Conference on Lung Cancer (ePosters)-EP16.03-005. Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists

EP16.03-005. Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists

Back to course

Pdf Summary

This document is a summary of a survey conducted to investigate the biomarker testing practices for Non-Small Cell Lung Cancer (NSCLC) in Australia. The survey involved medical oncologists and pathologists from different institutions. <br /><br />The survey results showed that reflex testing, which is testing initiated automatically by pathologists upon diagnosis of NSCLC, was performed for all stages of the disease. The majority of respondents were from public metropolitan institutions, with varying years of experience in NSCLC. <br /><br />In terms of the location of molecular testing, a combination of in-house and outsourced testing was reported. The turn-around time for results varied, with the majority of respondents receiving results within 7-14 days. The type of assay used for molecular testing also varied, with a majority of respondents using multi-gene Next-Generation Sequencing (NGS) assays.<br /><br />The survey also looked at KRAS mutation testing specifically. The majority of respondents reported routine testing for KRAS mutations, with some barriers identified such as lack of reimbursement, lack of clinical trials, and cost.<br /><br />Overall, the survey results provide insights into the current practices of biomarker testing for NSCLC in Australia. It highlights the use of reflex testing, the adoption of NGS assays, and the challenges in routine KRAS testing. These findings can inform future research and clinical practices in the field of lung cancer biomarker testing.

Asset Subtitle

Ben Markman

Meta Tag

Speaker Ben Markman

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

survey

biomarker testing

NSCLC

Australia

reflex testing

molecular testing

NGS assays

KRAS mutation testing

reimbursement

challenges